The campaign against drug TV advertising and marketing seems to be accelerating in Washington and around the country. The latest salvo comes from leaders of the House Energy & Commerce Committee who want information from pharmaceutical companies and the Food and Drug Administration about questionable marketing campaigns.
The campaign against drug TV advertising and marketing seems to be accelerating in Washington and around the country. The latest salvo comes from leaders of the House Energy & Commerce Committee who want information from pharmaceutical companies and the Food and Drug Administration about questionable marketing campaigns.
E&C Chairman John Dingell and Oversight Subcommittee Chairman Bart Stupak, both Michigan Democrats, are questioning the use of celebrity spokesman Dr. Robert Jarvik in Pfizer commercials for Lipitor (atorvastatin). The legislators consider the ads misleading because Jarvik is not a heart specialist and didn’t perform the energetic rowing shown in TV commercials featuring his comments.
Celebrity endorsements are problematic for any DTC advertising, according to the investigators. However, they consider it particularly troubling to use stunt doubles in ads designed to emphasize a medicine’s powerful effectiveness.
The crack-down on Lipitor ads by the House committee follows their investigation into ads for Vytorin promoting the drugs effectiveness, which subsequently came into question. The committee demanded that FDA provide it with all agency records relating to print, broadcast and internet advertising for Vytorin, which brought in boxes of documents and disks. In addition, co-marketers Merck and Schering-Plough halted consumer advertising of Vytorin.
Unrealistic Portrayals of Cardiac Arrest in Contemporary Film | ACC 2025
March 31st 2025Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
March 31st 2025In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.
Read More
Clopidogrel Beat Aspirin in Preventing Heart Attacks After PCI | ACC 2025
March 31st 2025Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.
Read More